New pill for eczema and psoriasis enters early safety testing
NCT ID NCT06982352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through the body. This is a Phase 1 trial, so it focuses on safety first.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Investigations of Texas
RECRUITINGDallas, Texas, 75075, United States
Contact Email: •••••@•••••
-
Red River Research Partners
RECRUITINGFargo, North Dakota, 58103, United States
-
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITINGAmman, Jordan, B204, Jordan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common blood thinner shield psoriasis Patients' arteries?
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Can a new pill tame psoriasis? early safety trial begins
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin